Originally published by our sister publication Gastroenterology & Endoscopy News
CHICAGO—In patients with obesity and metabolic dysfunction–associated steatotic liver disease, treatment with endoscopic sleeve gastroplasty led to more weight loss and significantly greater improvements in hepatic steatosis index than treatment with the glucagon-like peptide-1 agonist semaglutide.
A large majority of patients with obesity—some studies have found up to 90% of patients—also